-+ 0.00%
-+ 0.00%
-+ 0.00%

Standard BioTools agrees to merge with Treeline Biosciences in all-stock deal

PUBT·06/08/2026 12:33:03
Listen to the news
Standard BioTools agrees to merge with Treeline Biosciences in all-stock deal
  • Standard BioTools will merge with Treeline Biosciences in an all-stock deal; the combined company will operate as Treeline Biosciences under ticker TRLN.
  • Closing is expected in H2 2026; the transaction values Standard BioTools at about $460 million based on net cash delivered at closing.
  • Pro forma cash is expected to exceed $900 million at closing, including about $450 million of net cash contributed by Standard BioTools.
  • Legacy Standard BioTools shareholders are expected to own about 16% of the combined company; Treeline shareholders about 84%, subject to net-cash adjustments.
  • Standard BioTools is exploring divestiture options for its Mass Cytometry and Microfluidics businesses, which Treeline does not plan to operate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-071195), on June 08, 2026, and is solely responsible for the information contained therein.